Publications by authors named "Jeremy Bastid"

Claim this Profile
A
A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.
François Ducray, Carole Ramirez, Marie Robert, Maxime Fontanilles, Charlotte Bronnimann, Jeremy Bastid

Pharmaceutics· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dispensing Oral Temozolomide in Children: Precision and Stability of a Novel and Ready to Use Liquid Formulation in Comparison with Capsule Derived Mixtures.
Caroline Lemarchand, Hugues Bienaymé, André Rieutord, Samuel Abbou, Maxime Annereau, Jeremy Bastid

Pharmaceutics· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients.
Maxime Annereau, Mélanie Hinterlang, Hugues Bienayme, Gilles Vassal, Antoine Pinon, Jérémy Bastid

Pharmaceuticals (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer.
Jérémy Bastid, Cécile Dejou, Aurélie Docquier, Nathalie Bonnefoy

Front Immunol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis.
Jérémy Bastid, Nathalie Bonnefoy, Jean-François Eliaou, Armand Bensussan

Oncoimmunology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Laurent Gros, Carine Paturel, Ivan Perrot, Armand Bensussan, Jean-François Eliaou, Jérémy Bastid

Med Sci (Paris)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Ivan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, Séverine Augier, Aurélie Docquier, Jérémy Bastid

Cell Rep· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.
Emilie Laprevotte, Stéphanie Cochaud, Stanislas du Manoir, Marion Lapierre, Cécile Dejou, Jérémy Bastid

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Yacine Merrouche, Joseph Fabre, Herve Cure, Christian Garbar, Camille Fuselier, Jeremy Bastid

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism.
Patrik Sundström, Hanna Stenstad, Veronica Langenes, Filip Ahlmanner, Lisa Theander, Jérémy Bastid

Cancer Immunol Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.
Sarah Mombelli, Stéphanie Cochaud, Yacine Merrouche, Christian Garbar, Frank Antonicelli, Jérémy Bastid

Sci Rep· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.
Nathalie Bonnefoy, Jérémy Bastid, Gilles Alberici, Armand Bensussan, Jean-François Eliaou

Oncoimmunology· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Jeremy Bastid, Anne Regairaz, Nathalie Bonnefoy, Cécile Déjou, Jérôme Giustiniani

Cancer Immunol Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.
Stéphanie Cochaud, Jérôme Giustiniani, Clémence Thomas, Emilie Laprevotte, Christian Garbar, Jeremy Bastid

Sci Rep· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.
Mardi C Boer, Krista E van Meijgaarden, Jérémy Bastid, Tom H M Ottenhoff, Simone A Joosten

Eur J Immunol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations.
Jeremy Bastid

Cancer Metastasis Rev· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should we consider cancers as embryonic diseases or as consequences of stem-cell deregulation?
Jérémy Bastid, Alain Puisieux, Stéphane Ansieau

Clin Med Oncol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SNAIL family member SCRATCH1 is not expressed in human tumors.
Jérémy Bastid, Benjamin Pierre Bouchet, Claire Ciancia, Julie Pourchet, Carole Audoynaud

Oncol Rep· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.
Agnès Doreau, Alexandre Belot, Jérémy Bastid, Benjamin Riche, Marie-Claude Trescol-Biemont

Nat Immunol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early origin of cancer metastases: dissemination and evolution of premalignant cells.
Stéphane Ansieau, George Hinkal, Clémence Thomas, Jérémy Bastid, Alain Puisieux

Cell Cycle· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.
Stéphane Ansieau, Jeremy Bastid, Agnès Doreau, Anne-Pierre Morel, Benjamin P Bouchet

Cancer Cell· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis